Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 539 entries
Sorted by: Best Match Show Resources per page
Association of genotypes of rs671 within.

Cancer biology & medicine

Zhang LQ, Song X, Zhao XK, Huang J, Zhang P, Wang LW, Meng H, Ku JW, Kong GQ, Jiang T, Li XM, Lv XL, Ma T, Yuan G, Wu MJ, Hu SJ, Lv S, Zhang TJ, Ji LF, Fan ZM, Wang NC, Zhang YW, Zhou FY, Wang LD.
PMID: 28443204
Cancer Biol Med. 2017 Feb;14(1):60-65. doi: 10.20892/j.issn.2095-3941.2016.0089.

OBJECTIVE: : This study aimed to determine if gastric cardia adenocarcinoma (GCA) risk was associated with the lys (A or *2) allele at the rs671 (glu504lys) polymorphism within the aldehyde dehydrogenase 2 (METHODS: : We designed a case-control study...

Cite
Zhang LQ, Song X, Zhao XK, et al. Association of genotypes of rs671 within. Cancer Biol Med. 2017;14(1):60-65doi: 10.20892/j.issn.2095-3941.2016.0089.
Zhang, L. Q., Song, X., Zhao, X. K., Huang, J., Zhang, P., Wang, L. W., Meng, H., Ku, J. W., Kong, G. Q., Jiang, T., Li, X. M., Lv, X. L., Ma, T., Yuan, G., Wu, M. J., Hu, S. J., Lv, S., Zhang, T. J., Ji, L. F., Fan, Z. M., Wang, N. C., Zhang, Y. W., Zhou, F. Y., & Wang, L. D. (2017). Association of genotypes of rs671 within. Cancer biology & medicine, 14(1), 60-65. https://doi.org/10.20892/j.issn.2095-3941.2016.0089
Zhang, Lian-Qun, et al. "Association of genotypes of rs671 within." Cancer biology & medicine vol. 14,1 (2017): 60-65. doi: https://doi.org/10.20892/j.issn.2095-3941.2016.0089
Zhang LQ, Song X, Zhao XK, Huang J, Zhang P, Wang LW, Meng H, Ku JW, Kong GQ, Jiang T, Li XM, Lv XL, Ma T, Yuan G, Wu MJ, Hu SJ, Lv S, Zhang TJ, Ji LF, Fan ZM, Wang NC, Zhang YW, Zhou FY, Wang LD. Association of genotypes of rs671 within. Cancer Biol Med. 2017 Feb;14(1):60-65. doi: 10.20892/j.issn.2095-3941.2016.0089. PMID: 28443204; PMCID: PMC5365177.
Copy Download .nbib Format: NLM
Roles of Rap1 signaling in tumor cell migration and invasion.

Cancer biology & medicine

Zhang YL, Wang RC, Cheng K, Ring BZ, Su L.
PMID: 28443208
Cancer Biol Med. 2017 Feb;14(1):90-99. doi: 10.20892/j.issn.2095-3941.2016.0086.

Ras-associated protein-1 (Rap1), a small GTPase in the Ras-related protein family, is an important regulator of basic cellular functions (e.g., formation and control of cell adhesions and junctions), cellular migration, and polarization. Through its interaction with other proteins, Rap1...

Cite
Zhang YL, Wang RC, Cheng K, et al. Roles of Rap1 signaling in tumor cell migration and invasion. Cancer Biol Med. 2017;14(1):90-99doi: 10.20892/j.issn.2095-3941.2016.0086.
Zhang, Y. L., Wang, R. C., Cheng, K., Ring, B. Z., & Su, L. (2017). Roles of Rap1 signaling in tumor cell migration and invasion. Cancer biology & medicine, 14(1), 90-99. https://doi.org/10.20892/j.issn.2095-3941.2016.0086
Zhang, Yi-Lei, et al. "Roles of Rap1 signaling in tumor cell migration and invasion." Cancer biology & medicine vol. 14,1 (2017): 90-99. doi: https://doi.org/10.20892/j.issn.2095-3941.2016.0086
Zhang YL, Wang RC, Cheng K, Ring BZ, Su L. Roles of Rap1 signaling in tumor cell migration and invasion. Cancer Biol Med. 2017 Feb;14(1):90-99. doi: 10.20892/j.issn.2095-3941.2016.0086. PMID: 28443208; PMCID: PMC5365179.
Copy Download .nbib Format: NLM
2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma.

Cancer biology & medicine

Gao M, Ge M, Ji Q, Cheng R, Lu H, Guan H, Gao L, Guo Z, Huang T, Huang X, Li X, Lin Y, Liu Q, Ni X, Pan Y, Qin J, Shan Z, Sun H, Wang X, Xu Z, Yu Y, Zhao D, Zhang N, Zhang S, Zheng Y, Zhu J, Li D, Zheng X, Chinese Association Of Thyroid Oncology Cato Chinese Anti-Cancer Association.
PMID: 28948061
Cancer Biol Med. 2017 Aug;14(3):203-211. doi: 10.20892/j.issn.2095-3941.2017.0051.

No abstract available.

Cite
Gao M, Ge M, Ji Q, et al. 2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma. Cancer Biol Med. 2017;14(3):203-211doi: 10.20892/j.issn.2095-3941.2017.0051.
Gao, M., Ge, M., Ji, Q., Cheng, R., Lu, H., Guan, H., Gao, L., Guo, Z., Huang, T., Huang, X., Li, X., Lin, Y., Liu, Q., Ni, X., Pan, Y., Qin, J., Shan, Z., Sun, H., Wang, X., Xu, Z., Yu, Y., Zhao, D., Zhang, N., Zhang, S., Zheng, Y., Zhu, J., Li, D., Zheng, X., & Chinese Association Of Thyroid Oncology Cato Chinese Anti-Cancer Association. (2017). 2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma. Cancer biology & medicine, 14(3), 203-211. https://doi.org/10.20892/j.issn.2095-3941.2017.0051
Gao, Ming, et al. "2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma." Cancer biology & medicine vol. 14,3 (2017): 203-211. doi: https://doi.org/10.20892/j.issn.2095-3941.2017.0051
Gao M, Ge M, Ji Q, Cheng R, Lu H, Guan H, Gao L, Guo Z, Huang T, Huang X, Li X, Lin Y, Liu Q, Ni X, Pan Y, Qin J, Shan Z, Sun H, Wang X, Xu Z, Yu Y, Zhao D, Zhang N, Zhang S, Zheng Y, Zhu J, Li D, Zheng X, Chinese Association Of Thyroid Oncology Cato Chinese Anti-Cancer Association. 2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma. Cancer Biol Med. 2017 Aug;14(3):203-211. doi: 10.20892/j.issn.2095-3941.2017.0051. PMID: 28948061; PMCID: PMC5570598.
Copy Download .nbib Format: NLM
Enhancement of radiosensitization by metal-based nanoparticles in cancer radiation therapy.

Cancer biology & medicine

Su XY, Liu PD, Wu H, Gu N.
PMID: 25009750
Cancer Biol Med. 2014 Jun;11(2):86-91. doi: 10.7497/j.issn.2095-3941.2014.02.003.

Radiation therapy performs an important function in cancer treatment. However, resistance of tumor cells to radiation therapy still remains a serious concern, so the study of radiosensitizers has emerged as a persistent hotspot in radiation oncology. Along with the...

Cite
Su XY, Liu PD, Wu H, et al. Enhancement of radiosensitization by metal-based nanoparticles in cancer radiation therapy. Cancer Biol Med. 2014;11(2):86-91doi: 10.7497/j.issn.2095-3941.2014.02.003.
Su, X. Y., Liu, P. D., Wu, H., & Gu, N. (2014). Enhancement of radiosensitization by metal-based nanoparticles in cancer radiation therapy. Cancer biology & medicine, 11(2), 86-91. https://doi.org/10.7497/j.issn.2095-3941.2014.02.003
Su, Xiang-Yu, et al. "Enhancement of radiosensitization by metal-based nanoparticles in cancer radiation therapy." Cancer biology & medicine vol. 11,2 (2014): 86-91. doi: https://doi.org/10.7497/j.issn.2095-3941.2014.02.003
Su XY, Liu PD, Wu H, Gu N. Enhancement of radiosensitization by metal-based nanoparticles in cancer radiation therapy. Cancer Biol Med. 2014 Jun;11(2):86-91. doi: 10.7497/j.issn.2095-3941.2014.02.003. PMID: 25009750; PMCID: PMC4069802.
Copy Download .nbib Format: NLM
Bridging academic science and clinical research in the search for novel targeted anti-cancer agents.

Cancer biology & medicine

Matter A.
PMID: 26779369
Cancer Biol Med. 2015 Dec;12(4):316-27. doi: 10.7497/j.issn.2095-3941.2015.0079.

This review starts with a brief history of drug discovery & development, and the place of Asia in this worldwide effort discussed. The conditions and constraints of a successful translational R&D involving academic basic research and clinical research are...

Cite
Matter A. Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. Cancer Biol Med. 2015;12(4):316-27doi: 10.7497/j.issn.2095-3941.2015.0079.
Matter, A. (2015). Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. Cancer biology & medicine, 12(4), 316-27. https://doi.org/10.7497/j.issn.2095-3941.2015.0079
Matter, Alex. "Bridging academic science and clinical research in the search for novel targeted anti-cancer agents." Cancer biology & medicine vol. 12,4 (2015): 316-27. doi: https://doi.org/10.7497/j.issn.2095-3941.2015.0079
Matter A. Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. Cancer Biol Med. 2015 Dec;12(4):316-27. doi: 10.7497/j.issn.2095-3941.2015.0079. PMID: 26779369; PMCID: PMC4706519.
Copy Download .nbib Format: NLM
Pathological clavicular fracture as first presentation of renal cell carcinoma: a case report and literature review.

Cancer biology & medicine

Kong Y, Wang J, Li H, Guo P, Xu JF, Feng HL.
PMID: 26779378
Cancer Biol Med. 2015 Dec;12(4):409-12. doi: 10.7497/j.issn.2095-3941.2015.0033.

Renal cell carcinoma (RCC) accounts for approximately 3% of all cancer cases. RCCs usually metastasize to the lungs, bones, liver, or brain. Only

Cite
Kong Y, Wang J, Li H, et al. Pathological clavicular fracture as first presentation of renal cell carcinoma: a case report and literature review. Cancer Biol Med. 2015;12(4):409-12doi: 10.7497/j.issn.2095-3941.2015.0033.
Kong, Y., Wang, J., Li, H., Guo, P., Xu, J. F., & Feng, H. L. (2015). Pathological clavicular fracture as first presentation of renal cell carcinoma: a case report and literature review. Cancer biology & medicine, 12(4), 409-12. https://doi.org/10.7497/j.issn.2095-3941.2015.0033
Kong, Yan, et al. "Pathological clavicular fracture as first presentation of renal cell carcinoma: a case report and literature review." Cancer biology & medicine vol. 12,4 (2015): 409-12. doi: https://doi.org/10.7497/j.issn.2095-3941.2015.0033
Kong Y, Wang J, Li H, Guo P, Xu JF, Feng HL. Pathological clavicular fracture as first presentation of renal cell carcinoma: a case report and literature review. Cancer Biol Med. 2015 Dec;12(4):409-12. doi: 10.7497/j.issn.2095-3941.2015.0033. PMID: 26779378; PMCID: PMC4706516.
Copy Download .nbib Format: NLM
Cellular immunity augmentation in mainstream oncologic therapy.

Cancer biology & medicine

Chen D, Zhang X.
PMID: 28607803
Cancer Biol Med. 2017 May;14(2):121-128. doi: 10.20892/j.issn.2095-3941.2017.0022.

Anticancer immunotherapy has undergone a long evolving journey for decades, and has been dramatically applied to mainstream treatments in oncology in recent 5 years. This progress represents an advanced milestone following cytotoxic medicine and targeted therapy. Cellular immunity plays...

Cite
Chen D, Zhang X. Cellular immunity augmentation in mainstream oncologic therapy. Cancer Biol Med. 2017;14(2):121-128doi: 10.20892/j.issn.2095-3941.2017.0022.
Chen, D., & Zhang, X. (2017). Cellular immunity augmentation in mainstream oncologic therapy. Cancer biology & medicine, 14(2), 121-128. https://doi.org/10.20892/j.issn.2095-3941.2017.0022
Chen, Daohong, and Zhang, Xiaoshi. "Cellular immunity augmentation in mainstream oncologic therapy." Cancer biology & medicine vol. 14,2 (2017): 121-128. doi: https://doi.org/10.20892/j.issn.2095-3941.2017.0022
Chen D, Zhang X. Cellular immunity augmentation in mainstream oncologic therapy. Cancer Biol Med. 2017 May;14(2):121-128. doi: 10.20892/j.issn.2095-3941.2017.0022. PMID: 28607803; PMCID: PMC5444924.
Copy Download .nbib Format: NLM
Mesenchymal stromal cells' role in tumor microenvironment: involvement of signaling pathways.

Cancer biology & medicine

Nwabo Kamdje AH, Kamga PT, Simo RT, Vecchio L, Seke Etet PF, Muller JM, Bassi G, Lukong E, Goel RK, Amvene JM, Krampera M.
PMID: 28607804
Cancer Biol Med. 2017 May;14(2):129-141. doi: 10.20892/j.issn.2095-3941.2016.0033.

Mesenchymal stromal cells (MSCs) are adult multipotent stem cells residing as pericytes in various tissues and organs where they can differentiate into specialized cells to replace dying cells and damaged tissues. These cells are commonly found at injury sites...

Cite
Nwabo Kamdje AH, Kamga PT, Simo RT, et al. Mesenchymal stromal cells' role in tumor microenvironment: involvement of signaling pathways. Cancer Biol Med. 2017;14(2):129-141doi: 10.20892/j.issn.2095-3941.2016.0033.
Nwabo Kamdje, A. H., Kamga, P. T., Simo, R. T., Vecchio, L., Seke Etet, P. F., Muller, J. M., Bassi, G., Lukong, E., Goel, R. K., Amvene, J. M., & Krampera, M. (2017). Mesenchymal stromal cells' role in tumor microenvironment: involvement of signaling pathways. Cancer biology & medicine, 14(2), 129-141. https://doi.org/10.20892/j.issn.2095-3941.2016.0033
Nwabo Kamdje, Armel Herve, et al. "Mesenchymal stromal cells' role in tumor microenvironment: involvement of signaling pathways." Cancer biology & medicine vol. 14,2 (2017): 129-141. doi: https://doi.org/10.20892/j.issn.2095-3941.2016.0033
Nwabo Kamdje AH, Kamga PT, Simo RT, Vecchio L, Seke Etet PF, Muller JM, Bassi G, Lukong E, Goel RK, Amvene JM, Krampera M. Mesenchymal stromal cells' role in tumor microenvironment: involvement of signaling pathways. Cancer Biol Med. 2017 May;14(2):129-141. doi: 10.20892/j.issn.2095-3941.2016.0033. PMID: 28607804; PMCID: PMC5444925.
Copy Download .nbib Format: NLM
Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen.

Cancer biology & medicine

Zhang J, Qian X, Liu F, Guo X, Gu F, Fu L.
PMID: 29545966
Cancer Biol Med. 2018 Feb;15(1):29-38. doi: 10.20892/j.issn.2095-3941.2017.0122.

OBJECTIVE: Tamoxifen is used as a complementary treatment for estrogen receptor (ER)-positive breast cancer (BCa), but many patients developed resistance. The aim of this study was to examine the role of syndecan-binding protein (SDCBP) silencing in ER-positive BCa cells.METHODS:...

Cite
Zhang J, Qian X, Liu F, et al. Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen. Cancer Biol Med. 2018;15(1):29-38doi: 10.20892/j.issn.2095-3941.2017.0122.
Zhang, J., Qian, X., Liu, F., Guo, X., Gu, F., & Fu, L. (2018). Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen. Cancer biology & medicine, 15(1), 29-38. https://doi.org/10.20892/j.issn.2095-3941.2017.0122
Zhang, Jun, et al. "Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen." Cancer biology & medicine vol. 15,1 (2018): 29-38. doi: https://doi.org/10.20892/j.issn.2095-3941.2017.0122
Zhang J, Qian X, Liu F, Guo X, Gu F, Fu L. Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen. Cancer Biol Med. 2018 Feb;15(1):29-38. doi: 10.20892/j.issn.2095-3941.2017.0122. PMID: 29545966; PMCID: PMC5842332.
Copy Download .nbib Format: NLM
Calcium channel α2δ1 subunit as a novel biomarker for diagnosis of hepatocellular carcinoma.

Cancer biology & medicine

Amhimmid Badr S, Waheeb Fahmi M, Mahmoud Nomir M, Mohammad El-Shishtawy M.
PMID: 29545968
Cancer Biol Med. 2018 Feb;15(1):52-60. doi: 10.20892/j.issn.2095-3941.2017.0167.

OBJECTIVE: Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. The identification of new simple, inexpensive and highly accurate markers for HCC diagnosis and screening is needed. This case-control study evaluates the role of annexin A2 and voltage-gated...

Cite
Amhimmid Badr S, Waheeb Fahmi M, Mahmoud Nomir M, et al. Calcium channel α2δ1 subunit as a novel biomarker for diagnosis of hepatocellular carcinoma. Cancer Biol Med. 2018;15(1):52-60doi: 10.20892/j.issn.2095-3941.2017.0167.
Amhimmid Badr, S., Waheeb Fahmi, M., Mahmoud Nomir, M., & Mohammad El-Shishtawy, M. (2018). Calcium channel α2δ1 subunit as a novel biomarker for diagnosis of hepatocellular carcinoma. Cancer biology & medicine, 15(1), 52-60. https://doi.org/10.20892/j.issn.2095-3941.2017.0167
Amhimmid Badr, Sana, et al. "Calcium channel α2δ1 subunit as a novel biomarker for diagnosis of hepatocellular carcinoma." Cancer biology & medicine vol. 15,1 (2018): 52-60. doi: https://doi.org/10.20892/j.issn.2095-3941.2017.0167
Amhimmid Badr S, Waheeb Fahmi M, Mahmoud Nomir M, Mohammad El-Shishtawy M. Calcium channel α2δ1 subunit as a novel biomarker for diagnosis of hepatocellular carcinoma. Cancer Biol Med. 2018 Feb;15(1):52-60. doi: 10.20892/j.issn.2095-3941.2017.0167. PMID: 29545968; PMCID: PMC5842334.
Copy Download .nbib Format: NLM
Parkin protein expression and its impact on survival of patients with advanced colorectal cancer.

Cancer biology & medicine

da Silva-Camargo CCV, Svoboda Baldin RK, Costacurta Polli NL, Agostinho AP, Olandosk M, de Noronha L, Sotomaior VS.
PMID: 29545969
Cancer Biol Med. 2018 Feb;15(1):61-69. doi: 10.20892/j.issn.2095-3941.2017.0136.

OBJECTIVE: Features of colorectal cancer such as natural history, molecular, chromosomal, and epigenetic alterations have been well described. However, there is still a lack of accurate prognostic markers, which is evident by the lower overall survival rates of patients...

Cite
da Silva-Camargo CCV, Svoboda Baldin RK, Costacurta Polli NL, et al. Parkin protein expression and its impact on survival of patients with advanced colorectal cancer. Cancer Biol Med. 2018;15(1):61-69doi: 10.20892/j.issn.2095-3941.2017.0136.
da Silva-Camargo, C. C. V., Svoboda Baldin, R. K., Costacurta Polli, N. L., Agostinho, A. P., Olandosk, M., de Noronha, L., & Sotomaior, V. S. (2018). Parkin protein expression and its impact on survival of patients with advanced colorectal cancer. Cancer biology & medicine, 15(1), 61-69. https://doi.org/10.20892/j.issn.2095-3941.2017.0136
da Silva-Camargo, Claudia Caroline Veloso, et al. "Parkin protein expression and its impact on survival of patients with advanced colorectal cancer." Cancer biology & medicine vol. 15,1 (2018): 61-69. doi: https://doi.org/10.20892/j.issn.2095-3941.2017.0136
da Silva-Camargo CCV, Svoboda Baldin RK, Costacurta Polli NL, Agostinho AP, Olandosk M, de Noronha L, Sotomaior VS. Parkin protein expression and its impact on survival of patients with advanced colorectal cancer. Cancer Biol Med. 2018 Feb;15(1):61-69. doi: 10.20892/j.issn.2095-3941.2017.0136. PMID: 29545969; PMCID: PMC5842336.
Copy Download .nbib Format: NLM
A new combined criterion to better predict malignant lesions in patients with pancreatic cystic neoplasms.

Cancer biology & medicine

Lan C, Li X, Wang X, Hao J, Ren H.
PMID: 29545970
Cancer Biol Med. 2018 Feb;15(1):70-78. doi: 10.20892/j.issn.2095-3941.2017.0152.

OBJECTIVE: Cystic lesions of the pancreas have been increasingly recognized. Some lesions exhibit benign behavior, while others have unequivocal malignant potential. Thus, accurate identification of malignancy in patients diagnosed with pancreatic cystic neoplasms (PCNs) remains a major challenge. The...

Cite
Lan C, Li X, Wang X, et al. A new combined criterion to better predict malignant lesions in patients with pancreatic cystic neoplasms. Cancer Biol Med. 2018;15(1):70-78doi: 10.20892/j.issn.2095-3941.2017.0152.
Lan, C., Li, X., Wang, X., Hao, J., & Ren, H. (2018). A new combined criterion to better predict malignant lesions in patients with pancreatic cystic neoplasms. Cancer biology & medicine, 15(1), 70-78. https://doi.org/10.20892/j.issn.2095-3941.2017.0152
Lan, Chungen, et al. "A new combined criterion to better predict malignant lesions in patients with pancreatic cystic neoplasms." Cancer biology & medicine vol. 15,1 (2018): 70-78. doi: https://doi.org/10.20892/j.issn.2095-3941.2017.0152
Lan C, Li X, Wang X, Hao J, Ren H. A new combined criterion to better predict malignant lesions in patients with pancreatic cystic neoplasms. Cancer Biol Med. 2018 Feb;15(1):70-78. doi: 10.20892/j.issn.2095-3941.2017.0152. PMID: 29545970; PMCID: PMC5842337.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 539 entries